Prediction of cyclosporine clearance in liver transplant recipients by the use of midazolam as a cytochrome P450 3A probe

Clinical Pharmacology and Therapeutics

Volumn 67, Issue 3, 2000, Pages 242-248

  Villeneuve, Jean Pierre ^a   L'Ecuyer, Lyne ^b   De Maeght, Stéphane ^b   Bannon, Pierre ^b  

^a UNIVERSITY OF MONTREAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; AZATHIOPRINE; CYCLOSPORIN A; CYTOCHROME P450 3A; MIDAZOLAM; PREDNISONE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG METABOLISM; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; GAS CHROMATOGRAPHY; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; MALE; MASS SPECTROMETRY; POSTOPERATIVE COMPLICATION; PREDICTION; PRIORITY JOURNAL;

EID: 0034024696     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.104642     Document Type: Article

References (30)

1. 1. Venkataramanan R, Burckhart GJ, Ptachcinski RJ. Pharmacokinetics and monitoring of cyclosporine following orthotopic liver transplantation. Semin Liver Dis 1985; 5:357-68.
2. 2. Cakaloglu Y, Tredger JM, Devlin J, Williams R. Importance of cytochrome P450IIIA activity in determining dosage and blood levels of FK506 and cyclosporine in liver transplant recipients. Hepatology 1994;20:309-16.
3. 3. Lindholm A, Henricsson S, Lind M, Dahlqvist R. Intraindividual variability in the relative systemic availability of cyclosporin after oral dosing. Eur J Clin Pharmacol 1988;34:461-4.
4. 4. Kronbach T, Fischer V, Meyer VA. Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988;43:630-5.
5. 5. Kolars JC, Awni WM, Merion RM, Watkins PB. First-pass metabolism of cyclosporin by the gut. Lancet 1991;338:1488-90.
6. 6. Schellens JH, Soons PA, Breimer DD. Lack of bimodality in nifedipine kinetics in a large population of healthy subjects. Biochem Pharmacol 1988;37:2507-10.
7. 7. Watkins PB, Murray SA, Winkelman LG, Heuman DM, Wrighton SA, Guzelian PS. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochrome P-450: studies in rats and patients. J Clin Invest 1989;83:688-97.
8. 8. May DG, Porter J, Wilkinson GR, Branch RA. Frequency distribution of dapsone N-hydroxylase, a putative probe for P4503A4 activity, in a white population. Clin Pharmacol Ther 1994;55:492-500.
9. 9. Watkins PB, Hamilton TA, Annesley TM, Ellis CN, Kolars JC, Voorhees JJ. The erythromycin breath test as a predictor of cyclosporine blood levels. Clin Pharmacol Ther 1990;48:120-9.
10. 10. Turgeon DK, Normolle DP, Leichtman AB, Annesley TM, Smith DE, Watkins PB. Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients. Clin Pharmacol Ther 1992;52:471-8.
11. 11. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager W F, Hartwell PS, et al. Use of midazolam as a human cytochrome P450 3A probe; I: in vitro-in vivo correlations in liver transplant patients. J Pharmacol Exp Ther 1994;271:549-56.
12. 12. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, Bacchi CE, et al. Use of midazolam as a human cytochrome P450 3A probe; II: characterization of inter-and intra-individual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther 1994;271:557-66.
13. 13. Kovarik JM, Mueller EA, van Bree JB, Arns W, Renner E, Kutz K. Within-day consistency in cyclosporine pharmacokinetics from a microemulsion formulation in renal transplant patients. Ther Drug Monit 1994;16:232-7.
14. 14. Coukell AJ, Plosker GL. Cyclosporin microemulsion (Neoral): a pharmacoeconomic review of its use compared with standard cyclosporin in renal and hepatic transplantation. Pharmacoeconomics 1998;14:691-708.
15. 15. Burtis CA, Ashwood ER. Tietz textbook of clinical chemistry. 2nd ed. Philadelphia: WB Saunders; 1994. p. 327.
16. 16. Watkins PB. Noninvasive tests for CYP3A enzymes. Pharmacogenetics 1994;4:171-84.
17. 17. Turgeon DK, Leichtman AB, Lown KS, Normolle DP, Deeb GM, Merion RM, et al. P450 3A activity and cyclosporine dosing in kidney and heart transplant recipients. Clin Pharmacol Ther 1994;56:253-60.
18. 18. Stein CM, Kinirons MT, Pincus T, Wilkinson GR, Wood AJJ. Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine. Clin Pharmacol Ther 1996;59:47-51.
19. 19. Primmett DRN, Levine M, Kovarik JM, Mueller EA, Keown PA. Cyclosporine monitoring in patients with renal transplants: two-or three-point methods that estimate area under the curve are superior to trough levels in predicting drug exposure. Ther Drug Monit 1998;20:276-83.
20. 20. Levy GA, Murphy GF, Keown PA. Cyclosporine: role of pharmacokinetics. Transplantation [in press].
21. 21. Thummel KE, O'Shea D, Payne MF, Shen DD, Kunze KL, Perkins JD, et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin Pharmacol Ther 1996;59:491-502.
22. 22. Hebert MF, Roberts JP, Prueksaritanont T, Benet LZ. Unavailability of cyclosporine with concomitant rifampin administration is markedly less than predicted by hepatic enzyme induction. Clin Pharmacol Ther 1992;52:453-7.
23. 23. Gomez DY, Wacher VJ, Tomlanovich SJ, Hebert MF, Benet LZ. The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine. Clin Pharmacol Ther 1995;58:15-9.
24. 24. Wu CY, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY, et al. Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 1995;58:492-7.
25. 25. Paine MF, Shen DD, Kunze KL, Perkins JD, Marsh CL, McVicar JP, et al. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996;60:14-24.
26. 26. Lown KS, Kolars JC, Thummel KE, Barnett JL, Kunze KL, Wrighton SA, et al. Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel: lack of prediction by the erythromycin breath test. Drug Metab Dispos 1994;22:947-55.
27. 27. Lown KS, Mayo RR, Leichtman AB, Hsiao H, Turgeon DK, Schmiedlin-Ren P, et al. Role of intestinal P-glyco-protein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997;62:248-60.
28. 28. Edwards DJ, Fitzsimmons ME, Schuetz EG, Yasuda K, Ducharme MP, Warbasse LH, et al. 6′,7′-Dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein. Clin Pharmacol Ther 1999;65:237-44.
29. 29. Mehta MU, Venktaramanan R, Burckhardt GJ, Starzl TE. Effect of bile on cyclosporin absorption in liver transplant patients. Br J Clin Pharmacol 1988;25:579-81.
30. 30. Lemaire M, Fahr A, Maurer G. Pharmacokinetics of cyclosporin: inter-and intra-individual variations and metabolic pathways. Transplant Proc 1990;22:1110-2.